Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_1
3
75%
Ph phase_2
1
25%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants

NCT04427917
completedphase_2

A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

NCT03969719
completedphase_1

Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects

NCT02974374
completedphase_1

Multiple Ascending Dose and DDI Study

NCT03031119

Clinical Trials (4)

Showing 4 of 4 trials
NCT04427917Phase 1

Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants

Completed
NCT03969719Phase 2

A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Completed
NCT02974374Phase 1

Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects

Completed
NCT03031119Phase 1

Multiple Ascending Dose and DDI Study

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4